[go: up one dir, main page]

NO20000823L - Et middel for Õ fremme sekresjon av veksthormon - Google Patents

Et middel for Õ fremme sekresjon av veksthormon

Info

Publication number
NO20000823L
NO20000823L NO20000823A NO20000823A NO20000823L NO 20000823 L NO20000823 L NO 20000823L NO 20000823 A NO20000823 A NO 20000823A NO 20000823 A NO20000823 A NO 20000823A NO 20000823 L NO20000823 L NO 20000823L
Authority
NO
Norway
Prior art keywords
growth hormone
promote secretion
secretion
promote
hormone
Prior art date
Application number
NO20000823A
Other languages
English (en)
Other versions
NO20000823D0 (no
Inventor
Jeffrey Alan Dodge
Kenneth Lee Hauser
Mark Louis Heiman
Scott Alan Jones
Charles Arthur Alt
Henry Uhlman Bryant
Jeffrey Daniel Cohen
James Densmore Copp
Kennan Joseph Fahey
William Harlan Gritton
Louis Nickolaus Jungheim
Joseph Henry Kennedy
Iii Charles Willis Lugar
Brian Stephen Muehl
Alan David Palkowitz
Andrew Michael Ratz
Gary Anthony Rhodes
Robert Lewis Robey
David Edward Seyler
Timothy Alan Shepherd
Kenneth Jeff Thrasher
William George Trankle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20000823D0 publication Critical patent/NO20000823D0/no
Publication of NO20000823L publication Critical patent/NO20000823L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20000823A 1997-08-19 2000-02-18 Et middel for Õ fremme sekresjon av veksthormon NO20000823L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5614297P 1997-08-19 1997-08-19
PCT/US1998/017229 WO1999008699A1 (en) 1997-08-19 1998-08-19 Growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NO20000823D0 NO20000823D0 (no) 2000-02-18
NO20000823L true NO20000823L (no) 2000-04-12

Family

ID=22002443

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000823A NO20000823L (no) 1997-08-19 2000-02-18 Et middel for Õ fremme sekresjon av veksthormon

Country Status (24)

Country Link
EP (1) EP0933365A3 (no)
JP (1) JP2001515046A (no)
KR (1) KR20010027947A (no)
CN (1) CN1243567C (no)
AR (1) AR018010A1 (no)
AU (1) AU738204B2 (no)
BR (1) BR9811948A (no)
CA (1) CA2302467A1 (no)
CO (1) CO5121066A1 (no)
EA (1) EA002746B1 (no)
HR (1) HRP20000090A2 (no)
HU (1) HUP0002392A3 (no)
ID (1) ID25000A (no)
IL (1) IL134596A0 (no)
MY (1) MY138258A (no)
NO (1) NO20000823L (no)
NZ (1) NZ502947A (no)
PE (1) PE115999A1 (no)
PL (1) PL338883A1 (no)
TR (1) TR200000930T2 (no)
TW (1) TW577879B (no)
UA (1) UA58472C2 (no)
WO (1) WO1999008699A1 (no)
ZA (1) ZA987385B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010565A1 (en) * 1998-08-18 2000-03-02 Eli Lilly And Company Growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6417397B1 (en) 1999-10-04 2002-07-09 The Regents Of The University Of California, San Diego N-substituted alkylamino acids for use as amino-protecting groups
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
US20040106665A1 (en) * 2000-10-13 2004-06-03 Kress Thomas Joseph Resolution process for preparation of substantially pure (r) and (s) enantiomers of 2-(4-nitroimidazolyl)-4-methodxyphenylpropionic acid and salts thereof
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
EP1572668A4 (en) * 2002-12-18 2006-12-06 Fmc Corp N- (SUBSTITUTED ARYLMETHYL) -4- (DISUBSTITUTE-METHYL) PIPERIDINE AND PIPERAZINE
ES2308441T3 (es) 2004-03-23 2008-12-01 Pfizer Products Incorporated Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos.
AU2006293619A1 (en) 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
BR112014026210A2 (pt) 2012-05-03 2017-06-27 Novartis Ag derivados de sal l-malato de 2,7-diaza-espiro[4.5]dec-7-il e formas cristalinas dos mesmos como agonistas do receptor de grelina
MX368059B (es) 2013-07-18 2019-09-18 Novartis Ag Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica.
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
JP6625541B2 (ja) * 2014-08-29 2019-12-25 東京応化工業株式会社 イミダゾール化合物、金属表面処理液、金属の表面処理方法、及び積層体の製造方法
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN107286041A (zh) * 2016-04-01 2017-10-24 成都川科化工有限公司 一种n,n-二乙基甲酰胺的制备方法
CN108299218A (zh) * 2017-01-12 2018-07-20 南京红杉生物科技有限公司 一种4-溴-d-苯丙氨酸的合成方法
CN110128285B (zh) * 2019-06-24 2022-03-01 华北制药股份有限公司 D-苯甘氨酸甲酯盐酸盐/d-二氢苯基甘氨酸甲酯盐酸盐的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
RU2168512C2 (ru) * 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
BR9407869A (pt) * 1993-10-19 1996-10-29 Merck & Co Inc Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
AU6724496A (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
EP0761220A1 (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamides as growth hormone secretagogues

Also Published As

Publication number Publication date
EA002746B1 (ru) 2002-08-29
ZA987385B (en) 2000-04-18
WO1999008699A1 (en) 1999-02-25
NZ502947A (en) 2001-11-30
TW577879B (en) 2004-03-01
BR9811948A (pt) 2000-08-22
EA200000239A1 (ru) 2000-10-30
CN1276727A (zh) 2000-12-13
EP0933365A3 (en) 2003-03-19
IL134596A0 (en) 2001-04-30
EP0933365A2 (en) 1999-08-04
JP2001515046A (ja) 2001-09-18
NO20000823D0 (no) 2000-02-18
HRP20000090A2 (en) 2001-04-30
AU9025698A (en) 1999-03-08
CA2302467A1 (en) 1999-02-25
AR018010A1 (es) 2001-10-31
ID25000A (id) 2000-09-07
KR20010027947A (ko) 2001-04-06
TR200000930T2 (tr) 2000-11-21
CO5121066A1 (es) 2002-01-30
UA58472C2 (uk) 2003-08-15
HUP0002392A3 (en) 2000-11-28
AU738204B2 (en) 2001-09-13
CN1243567C (zh) 2006-03-01
PL338883A1 (en) 2000-11-20
MY138258A (en) 2009-05-29
PE115999A1 (es) 1999-11-26
HUP0002392A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
NO20000823L (no) Et middel for Õ fremme sekresjon av veksthormon
DK0869968T3 (da) Væksthormonsecerneringsfremmende stof
DE69837264D1 (de) Dipeptidderivate zur förderung der sekretion von wachstumshormon
FI974368L (fi) Kasvuhormonin vapautumista edistäviä dipeptidejä
NO996469L (no) Tartratsalt av et substituert dipeptid som et veksthormonutskillelsesmiddel
IS5148A (is) Efnasambönd til að hindra magasýruseytrun
IS5272A (is) Nýtt form S-ómeprasóls
DK1289951T3 (da) Væksthormon sekretionsfremmere
DE69714582D1 (de) Katheter zur lokalen verabreichung einer therapeutisch aktiven substanz
ATE375996T1 (de) Sekretionsfordermittel fur wachtumshormon
ATA191697A (de) Arzneimittel zur förderung der wundheilung
FR2794169B1 (fr) Procede de controle de la capacite de fonctionnement d'un pot catalytique
DE69933057D1 (de) Analoge des humanen basischen fibroblasten-wachstumsfactors
ID24861A (id) Proses untuk membuat perangsang sekresi hormon pertumbuhan
FI940511A0 (fi) Menetelmä ferrisulfaatin valmistamiseksi
ID24327A (id) Produksi senyawa-senyawa avermektin
FI981474A0 (fi) Kantajien varausmenetelmä
NO20010828L (no) Tidsforskyvningsteknikk for Õ øke kapasiteten i et kommunikasjonssystem av kategori CDMA
FI972968L (fi) Menetelmiä kasvuhormonivaikutusten estämiseksi
FR2766334B1 (fr) Installation pour parer les brocolis
ID23019A (id) Metode pembuatan turunan nitroguadinin
ZA200000771B (en) Homeopathic preparations of purified growth hormone.
PL340458A1 (en) Production of therasosine chlorhydride dihydrate
FI101787B1 (fi) Kipsin puhdistusmenetelmä
EE200100562A (et) Meetod sidesüsteemi uute teenuste lisamise hõlbustamiseks

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application